Literature DB >> 4016156

Accumulation of N-acetylneuraminic acid (sialic acid) in human fibroblasts cultured in the presence of N-acetylmannosamine.

G H Thomas, J Scocca, C S Miller, L W Reynolds.   

Abstract

Human skin fibroblasts incubated for 72 h in medium containing 10 mM N-acetyl-D-mannosamine accumulate material that yields a chromophore in the presence of thiobarbituric acid. This material was tentatively identified as free (unbound) sialic acid due to its reactivity with thiobarbituric acid prior to acid hydrolysis, its solubility in 10% trichloroacetic acid, its chromatographic properties on an anion-exchange column and its enzymatic susceptibility to acylneuraminate pyruvate-lyase. Mass spectrometry analysis established that the accumulated material was, in fact, N-acetylneuraminic acid. Loading studies demonstrated a linear relationship between the amount of N-acetylmannosamine in the medium and the level of sialic acid accumulating within the cells. Cells grown in the absence of N-acetylmannosamine contained an average of 5 nmol free sialic acid/mg protein, while cells cultured for 72 h in 20 mM amounts of this material contained an average of 156.3 nmol free sialic acid/mg protein. When the cells were removed from the N-acetylmannosamine-enriched medium and incubated in regular medium, more than 80% of the accumulated, intracellular sialic acid disappeared within the first 96 h. It was concluded from these data that normal fibroblasts cultured in medium enriched with N-acetylmannosamine store large amounts of N-acetylneuraminic acid and can thus serve as an excellent model for the study of both normal and abnormal sialic acid metabolism, transport, storage and/or metabolic (feedback) regulation in human tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4016156     DOI: 10.1016/0167-4889(85)90107-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Purification and characterization of sialic acid containing materials accumulated in cultured skin fibroblasts from a patient with type II sialidosis.

Authors:  J R Scocca; G H Thomas; C Miller; L Reynolds
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

2.  Accumulation of [3H]sialyl-conjugates in sialidosis (sialidase-deficient) fibroblasts cultured in the presence of [3H]-N-acetylmannosamine.

Authors:  J Scocca; G H Thomas; L Reynolds; C S Miller
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Correction of sphingomyelinase deficiency in Niemann-Pick type C fibroblasts by removal of lipoprotein fraction from culture media.

Authors:  G H Thomas; C M Tuck-Muller; C S Miller; L W Reynolds
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

4.  Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.

Authors:  Xin Xu; Amy Q Wang; Lea L Latham; Frank Celeste; Carla Ciccone; May Christine Malicdan; Barry Goldspiel; Pramod Terse; James Cradock; Nora Yang; Selwyn Yorke; John C McKew; William A Gahl; Marjan Huizing; Nuria Carrillo
Journal:  Mol Genet Metab       Date:  2017-04-26       Impact factor: 4.797

5.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

6.  Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy.

Authors:  Scott Van Wart; Donald E Mager; Cindy J Bednasz; Marjan Huizing; Nuria Carrillo
Journal:  Drugs R D       Date:  2021-04-24

7.  Rationale and Design for a Phase 1 Study of N-Acetylmannosamine for Primary Glomerular Diseases.

Authors:  Marjan Huizing; Tal Yardeni; Federico Fuentes; May C V Malicdan; Petcharat Leoyklang; Alexander Volkov; Benjamin Dekel; Emily Brede; Jodi Blake; Alva Powell; Harish Chatrathi; Yair Anikster; Nuria Carrillo; William A Gahl; Jeffrey B Kopp
Journal:  Kidney Int Rep       Date:  2019-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.